Nebenwirkungen · Rayvow
RAYVOW 50 mg film-coated tablets RAYVOW 100 mg film-coated tablets RAYVOW 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 7
HOS-146406 · Präparat HOS-099510
Blood pressure increase Single dose administration of lasmiditan may lead to a transient increase in blood pressure. In non-elderly healthy volunteers a mean increase from baseline in ambulatory systolic and diastolic blood pressure of approximately 2 to 3 mm Hg one hour after administration of 200 mg lasmiditan was observed, compared to an increase of about 1 mm Hg for placebo. In healthy volunteers over 65 years of age, the mean increase from baseline in ambulatory systolic blood pressure was 7 mm Hg one hour after administration of 200 mg lasmiditan compared to a mean increase of 4 mm Hg for placebo. By 2 hours, there were no increases in mean blood pressure with lasmiditan compared to placebo. Clinical data for the use of lasmiditan in patients with ischemic heart disease is limited.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T14:15:00Z · SHA-256 1e249810461a190ad08f26cfa9c8836cc5710c80820c828a4ea6df354808f0a7 · Passage 7c73ebd237c88d24a4e45c292c8f88f6943e1a5b59e37fbfe78566b7354a328a · Zeichen 3391–4189 im Abschnitt